# Antiviral 2 deoxyuridines, their preparation and use.

## Abstract
Compounds of formula I

## Claims
CLAIMS 1. A compound of formula I EMI49.1 or a salt thereof, in which Y is a halogen atom, and each of R1 andR2 is a hydrogen atom or an acylamino group of the formula IA EMI49.2 which group is optionally N alkylated or acylated, wherein R3 is a hydrogen atom, or a C1 6 alkyl, phenyl, optionally substituted C1 6 phenylalkyl,C1 6 hydroxyalkyl, C16 aminoalkyl, optionally N substituted with C16 alkoxycarbonyl, C16 thioalkyl, C1 6 alkylthioalkyl, C16 carboxyalkyl or C1 6 carboxamidoalkyl group, R4 is a hydrogen atom or together with R3 forms the remaining members of a heterocyclic ring, and L is a hydrogen atom or a protecting group, provided that R1 and R2 are not simultaneously hydrogen atoms. 2. A compound according to claim 1, in which Y is a bromine atom. 3. A compound according to claim 1 or claim 2, in which R3 is a benzyl group optionally substituted by a halogen atom, or is a methyl, iso propyl or iso butyl group. 4. A compound according to claim 1 or claim 2, in which R3 and R4 complete a 5 to 7 membered saturated heterocyclic ring with no additional hetero atom present therein. 5. The compound E 5 2 bromovinyl 3 ,5 di L leucyl 2 deoxyuridine or a pharmaceutically acceptable salt thereof. 6. A process for preparing a compound according to claim 1, which comprises treating a compound of formula II EMI51.1 in which Y is as defined in formula I , with a compound of formula III EMI51.2 in which R3 and R4 are as defined in formula IA , L is a protecting group, and R5 is an active ester group, and optionally thereafter removing the protecting group L. 7. A process according to claim 6, in which R5 is a N hydroxy succinimide group or a p nitrophenyl group. 8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 together with a pharmaceutically acceptable carrier. 9. A compound according to any one of claims 1 to 5, for use in the treatment of viral infections.

## Description
ANTIVIRAL AGENTS, THEIR PREPARATION AND USE This invention relates to certain deoxyuridine compounds which have antiviral activity. U.K. Patent Spectification No. 1,601,020 discloses 5 2 halogenovinyl 2 deoxyuridines which have ntiviral activity selective against herpes virus. We have now found a group of mono and di aminoacyl derivatives of 5 2 halogenovinyl 2 deoxyuridine which have antiviral activity, and which are useful in the treatment of infections caused by herpes viruses, such as herpes simplex type 1, herpes simplex type 2 and varicella. According to the present invention there is provided an ester of the formula I EMI2.1 or a salt thereof, in which Y is a halogen atom, and each of R1 and R2 is a hydrogen atom or an acylamino group of the formula IA EMI2.2 which group is optionally N alkylated or acylated, wherein R3 is a hydrogen atom, or a C16 alkyl, phenyl, optionally substituted C1 6 phenylalkyl, C1 6 hydroxyalkyl, C1 6 aminoalkyl, optionally N substituted with C1 6 alkoxycarbonyl, C1 6 thioalkyl, C1 6 alkylthioalkyl, C1 6 carboxyalkyl or C16 carboxamidoalkyl group, R4 is a hydrogen atom or together with R3 forms the remaining members of a heterocyclic ring, andL is a hydrogen atom or a protecting group, provided that R1 and R2 are not simultaneously hydrogen atoms. Preferably, Y is a bromine atom. A preferred value for L is the tertiary butoxycarbonyl group. Suitably, R3 is an optionally substituted phenylalkyl group, preferably a benzyl group, optionally substituted by halogen, preferably fluorine. When R3 is a C1 6 alkyl group, it is preferably methyl, iso propyl or iso butyl. When R3 and R4 complete a heterocyclic ring, the ring is preferably a 5 to 7 membered saturated ring with no additional hetero atom present therein. Salts of the compounds of formula I are suitably acid addition salts formed with the amino group on the acylamino group of formula IA . Examples of these salts are pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide, and pharmaceutically acceptable organic acid addition salts such as the acetate and trifluoroacetate. The group of formula IA has an asymetric carbon atom, marked with an asterisk in the formula. The compounds of formula I therefore, exist in two stereoisomeric forms, and the present invention encompasses both stereoisomers alone or admixed in any proportion. The compounds of formula I may be prepared by reacting a compound of formula II EMI4.1 in which Y is as defined in formula I , with anN protected 2 amino carboxylic acid active ester, of formula III EMI4.2 in which R3 and R4 are as defined in formula I , L is a protecting group, and R5 is an active ester group, and optionally thereafter removing the protecting groupL. R5 may be any suitable active ester group, but preferred groups are the N hydroxysuccinimide group and the p nitrophenyl group. The reaction is preferably carried out in an inert solvent, such as dry tetrahydrofuran. The deprotection of the compounds of formula I is suitably carried out by treatment of the compounds with an acid, preferably trifluoroacetic or sulphuric acid. Preferred salts of the compounds of formula I are those which are formed as a result of the acid deprotection reaction. For example, treatment with sulphuric acid or trifluoroacetic acid provides the bisulphate or trifluoroacetate salts respectively. The reaction between the compounds of formulae II and III produces a mixture of three compounds, wherein a R1 hydrogen andEMI5.1 EMI5.2 andR2 hydrogen c R1 and R2 are bothEMI5.3 The three compounds may be separated chromatographically, suitably by column chromatography on silica gel. The compounds of formula I may be formulated for use in a pharmaceutical composition. Accordingly, in a further aspect of the invention, there is provided a pharmaceutical composition which comprises a compound bf the formula I together with a pharmaceutically acceptable carrier or excipient. Compositions which may be given by the oral route may be compounded in the form of syrups, tablets and capsules. When the composition is in the form of a tablet, any pharmaceutical carrier suitable for formulating such solid compositions may be used, for example magnesium stearate, starch, lactose, glucose, rice, flour and chalk. The composition may also be in the form of an ingestible capsule, for example of gelatin, to contain the compound, or in the form of a syrup, a solution or a suspension. Suitable liquid pharmaceutical carriers include ethyl alcohol, glycerine, saline and water to which flavouring or colouring agents may be added to form syrups. The compounds may also be presented with a sterile liquid carrier for injection. The composition may also be formulated for topical application to the skin or eyes. For topical application to the skin, the compounds of the invention may be made up into a cream, lotion or ointment. These formulations may be conventional formulations well known in the art, for example, as described in standard books of pharmaceutics and cosmetics, such as Harry s Cosmeticology published byLeonard Hill Books, and the British Pharmacopaeia. The composition for application to the eyes may be a conventional eye drop composition well known in the art. Preferably, the compositions of this invention are in unit dosage form or in some other form that the patient may administer to himself a single dose. A suitable dosage unit might contain from 50 mg to lg of active ingredient, for example 100 mg to 500 mg. Such doses may be administered 1 to 4 times a day or more usually 2 or 3 times a day. The effective dose of compound depends on the particular compound employed, but is in general in the range of from 1.0 mg kg day to 20 mg kg of body weight per day or more usually 2.0 mg kg day to 10 mg kg day. In a further aspect of the invention there is provided a method of treating viral infections in human or non human animals, which comprises administering to the sufferer an effective amount of a compound of formula I or a salt thereof. The following Examples illustrate the invention. Examples 1, 2 and 3Preparation ofE 5 2 bromovinyl 2 deoxyuridine 3 5 0 and 31 ,51 di 0 tert.butoxycarbonylphenylalanyl esters A mixture of E 5 2 bromovinyl 2 deoxyuridine 2g, 6.01 mmol , N tert. butoxycarbonylphenylalanine Nhydroxy succinimide ester 2.4 g, 6.62 mmol and 4 dimethylaminopyridine 0.4 g, 3.2 mmol were stirred together in dry tetrahydrofuran 100 ml at 750 for 3 hours. The solvent was removed under reduced pressure and the residue dissolved in dichloromethane 100 mL . The organic layer was washed with 1M hydrochloric acid 2 x 100 mL , cold saturated sodium hydrogen carbonate solution 2 x 100 mL and water 100 mL before drying Na2SO4 . The solvent was removed under reduced pressure affording a white foam. Thin layer chromatography of the foam on silica gel eluting with ehloroform methanol 20 1 showed the presence of three components Rf 0.60, 0.41, 0.21 . The three components ere separated by column chromatography on silica gel eluting with chloroform methanol 50 1 . The following three compounds were isolated by this method. Example No. Yield m.p. CExample 1E 5 2 Bromovinyl 3 ,5 di o tert butoxycarbonylphenylalanyl 2 30 foam deoxyuridine.Example 2E 5 2 bromovinyl 3 O tert butoxycarbonylphenylalanyl 2 16 98 102 deoxyuridine.Example 3 E 5 2 Bromovinyl 5 O tert butoxycarbonylphenylalanyl 2 32 114 6 deoxyurid ine Further characterising data for Example 1, 2 and 3 are as follows Example 1E 5 2 Bromovinyl 3 ,5 di O tert.butoxycarbonylphenylalanyl 2 deoxyuridineTlc Rf 0.60 in chloroform methanol 20 1 max nujol 3350 NH , 1750, 1700 C O cm 1, lHnmr CD3 2SO 1.37 18H, 2 x s, 6 x CH3 , 2.3 2H, m, 2 CH2 , 2.94 4H, m, 2EMI9.1 CH2 , 3.9 1H, m, 4 CH , 4.21 4H, m, 5 CH2 2x NH 5.0 1H, m, 3 CH , 6.07 1H, m, 1 CH , 6.92 1H, d, J 14Hz, CH CHBr , 7.3 13H, m, aromatic CH CHBr 2 x NHCH , 7.77 1H, s, 6 CH , 11.67 1H, br.s, D2O exchangeable, NH AnalysisFound C, 56.48 H, 5.58 N, 6.43. C3gH47N4OllBr requires C, 56.59 H, 5.72 N, 6.77. Example 2E 5 2 Bromovinyl 3 0 tert.butoxycarbonylphenylalanyl 2 deoxyuridineTlc Rf 0.41 in chloroform methanol 20 1 . max nujol 3400, 3500 NH, OH , br. 1700 C 0 cm 1 1H nmr CD3 2SO 1.4 9H, s, CH3 3 , 2.26 2H, m, 2 CH2 , 2.94 2H, m, Ph CH2 , 3.7 2H, m, 5 CH2 , 4.15 2H, m, 4 CH NHCEMI10.1 .21 2H, m, 1H D20 exchangeable, 3 CH 6.1 1H, m, 1 CH , 6.8 1H, d, J 14Hz, CH CHBr , 7.3 7H, m, aromatic CH CHBr NHCH , 8.03 1H, s, 6 CH , 11.6 1H, br.s, D2O exchangeable, NH .AnalysisFound C, 51.95 H, 5.01 N, 7.13. C25H30N308Br requires C, 51.73 H, 5.21 N, 7.24. Example 3E 5 2 Bromovinyl 5 O tert.butoxycarbonylphenylalanyl 2 deoxyuridineTic Rf 0.21 in chloroform methanol 20 1 . vmax nujol 3350 OH, NH , br.l700 C O cm 1.ÚHnmr CD3 2SO 1.37 9H, s, CH3 3 , 2.14 2H, m, 2 CH2 , 2.94 2H, m, PhCH2 , 3.9 1H, m, 4 CH , 4.2 4H, m, 5 CH2 3 CH EMI11.1 5.37 1H, d, J 4.5Hz,D2O exchangeable, OH ,H, t, J 6Hz, 1 CH , 6.94 1H, d, J 14Hz, CH CHBr , 7.29 7H, m, aromatic CH CHBr CHNH , 7.77 1H, s, 6 CH , 11.6 1H, br.s, D2O exchangeable, NH .AnalysisFound C, 52.05 H, 5.42 N, 7.05. C25H30N3O8Br requires C, 51.73 H, 5.21 N, 7.24. Examples 4, 5 and 6Preparation of E 5 2 Bromovinyl 2 deoxyuridine 3 5 O and 3 ,5 di O tert.butoxycarbonylglycyl esters The three glycyl esters were prepared as for the preparation of the phenylalanyl esters Examples 1, 2 and 3 . The crude reaction residue was a yellow foam which was shown by tlc in chloroform methanol 5 1 to be three components Rf 0.68, 0.57, 0.47 . The three components were separated by column chromatography on silica gel eluting with chloroform methanol 20 1 . The following three compounds were isolated by this method.Example No. Yield m.p. CExample 4 E 5 2 Bromovinyl 3 ,5 di O tert.butoxycarbonylglycyl 2 17 foam deoxyurdine.Example 5E 5 2 Bromovinyl 3 O tert.butoxycarbonylglycyl 2 4 foam deoxyurid ine. Example 6E 5 2 Bromovinyl 5 O tert.butoxycarbonylglycyl 2 30 112 4 deoxyuridine. Example 5 E 5 2 Bromovinyl 3 0 tert.butoxycarbonylglycyl 2 deoxyurid ine T1c Rf 0.57 in chloroform methanol 5 1 max nujol 3350 OH, NH . 1760, 1700 C 0 cm 1.1H n.m.r. CD3 2SO 1.4 9H, s, CH3 3 , 2.33 2H, m, 2 CH2 , 3.69 4H, m, 5 CH2 CH2 , 4.0 1H, m, 4 CH , 5.27 2H, m, 1H D2O exchangeable, 3 CH OH , 6.16 1H, t, J J 7.5Hz, 1 CH , 6.85 1H, d, J 14Hz, CH CHBr , 7.23 1H, br.s, NHCH2 , 7.26 1H, d, J 14Hz,CH CHBr , 8.06 1H, s, 6 CH , 11.62 1H, br.s, D2O exchangeable, NH AnalysisFound C, 44.06 H, 4.87 N, 8.10. C18H24N3O8Br requires C, 44.09 H, 4.93 N, 8.57. Example 5 E 5 2 BromovinyS 3 0 tert.butoxyearbonylglycyl 2 deoxyurid ine T1c Rf 0.57 in chloroform methanol 5 1 max nujol 3350 OH,NH , 1760, 1700 C O cm l. 1H n.m.r. CD3 2SO 1.4 9H, s, CH3 3 , 2.33 2H, m, 2 CH2 , 3.69 4H, m, 5 CH2 CH2 , 4.0 lH, m, 4 CH , 5.27 2H, m, 1H D2O exchangeable, 3 CH OH , 6.16 1H, t, J 7.5Hz, 1 CH , 6.85 lH, d, J 14Hz, CH CHBr , 7.23 1H, br.s, NHCH2 , 7.26 1H, d, J 14Hz,CH CHBr , 8.06 lH, s, 6 CH , 11.62 lH, br.s, D2O exchangeable, NH AnalysisFound C, 44.06 H, 4.87 N, 8.10. C18H24N3O8Br requires C, 44.09 H, 4.93 N, 8.57. Example 6 t 5 2 Bromovinyl 5 0 tert.butoxyzarbonylglycyl 2 deoxyurid ine T1c Rf 0.47 in chloroform methanol 5 1 max nujol 3500, 3350 OH, NH , 1760, 1690 C O cm 1 ÚHnmr CD3 2SO 1.4 9H, s, CH3 3 , 2.18 2H, m, 2 CH2 , 3.68 2H, d, J 6Hz, CH2 , 3.91 1H, m, 4 CH , 4.22 3H, m, 5 CH2 3 CH , 5.35 1H, br.s, D2O exchangeable, OH , 6.13 1H, t, J 5Hz, 1 CH , 6.87 1H, d, J 14Hz, CH CHBr , 7.2 1H, m, NHCH2 , 7.31 1H, d,J 14Hz, CH CHBr , 7.74 1H, s, 6 CH , 11.6 1H, br.s,D2O exchangeable, NH .AnalysisFound C, 44.20 H, 4.98 N, 8.31. C18H24N3O8Br requires C, 44.09 H, 4.93 N, 8.57. Examples 7, 8 and 9General method for the trifluoroacetic acid deprotection of E 5 2 Bromovinyl 2 deoxyuridine 3 5 O and 3 ,5 di O tert.butoxyearbonylphenylalanyl esters A solution of E 5 2 bromovinyl 2 deoxyuridine 3 5 O or 3 ,5 di O tert.butoxycarbonylphenyl alanyl esters 0.43 mmol in trifluoroacetic acid 3 mL was stirred at 250 for 15 minutes. The solvent was removed in vacuo and the oily residue triturated with dry ether to give a white solid. The following three compounds were prepared by this method.Example No.Example 7 Yield E 5 2 Bromovinyl 3 ,5 di O phenylalanyl2 deoxyuridine bis trifluoroacetate 79Example 8E 5 2 Bromovinyl 3 O phenylalanly 2 deoxyuridine trifluoroacetate 91Example 9E 5 2 Bromovinyl 5 O phenylalanyl 2 deoxyuridine trifluoroacetate 94 Further characterising data for Examples 7, 8 and 9 are as follows. Example 7E 5 2 Bromovinyl 3 ,5 di O phenylalanyl 2 deoxyuridine bis trifluoroacetate 1Hnmr CD3 2SO 2.3 2H, m, 2 CH2 , 3.18 4H, m, 2 x PhCH2 , 3.86 1H, m, 4 CH , 4.3 4H, m, 5 CH2 2xCH , 5.05 1H, m, 3 CH , 6.05 1H, t, J 7.5Hz, 1 CH , 6.9 1H, d, J 14Hz, CH CHBr , 7.35 llH, m, aromatic CH CHBr , 7.8 1H, s, 6 CH , 8.67 6H, br.s, D2O exchangeable, 2 x NH3 , 11.5 1H, br.s, D2O exchangeable, NH .AnalysisFound C, 46.54 H, 3.77 N, 6.24. C33H33N3BrF6O11 requires C, 46.33 H, 3.89 N, 6.55. Example 8E 5 2 Bromovinyl 3 0 phenylalanyl 2 deoxyuridine trifluoroacetate ÚHnmr CD3 2SO 2.28 2H, m, 2 CH2 , 3.08 2H, m, pHCH2 , 3.66 2H, m, 5 CH2 , 4.0 1H, m, 4 CH , 4.32 1H, t, J 7.5Hz, PhCH2CH , 5.24 2H, m, IH D20 exchangeable, 3 CH OH , 6.06 1H, t, J 7.5Hz, 1 CH , 6.84 1H, d, J 14Hz, CH CHBr , 7.3 6H, m, aromatic CH CHBr , 8.06 1H, s, 6 CH , 8.67 3H, br.s, D20 exchangeable, NH3 , 11.66 1H, br.s, D20 exchangeable,NH .AnalysisFound C, 44.29 H, 3.67 N, 6.82. C22H23N3BrF308 requires C, 44.46 H, 3.90 N, 7.07. Example 9 E 5 2 Bromovinyl 5 0 phenylalanyl 2 deoxyuridine trifluoroacetate 1Hnmr CD3 2SO s 2.2 2H, m, 2 CH2 , 3.13 2H, m,PhCH2 , 3.9 1H, m, 4 CH , 4.2 4H, m, 5 CH2 3 CH PhCH2CH , 6.19 1H, t, J 7.5Hz, 1 CH , 6.96 1H, t, J 14Hz, CH CHBr , 7.3 6H, m, aromatic CH CHBr , 7,8 1H, s, 6 CH , 8.62 3H, br.s,D2O exchangeable, NH3 , 11.7 1H, br.s, D2O exchangeable, NH .AnalysisFound C, 44.21 H, 3.85 N, 6.79. C22H23N3BrF308 requires C, 44.46 H, 3.90 N, 7.07. Example 10Method for the sulphuric acid deprotection of E 5 2 Bromovinyl 3 ,5 di O tert.butoxyzarbonyl phenylalanyl 2 deoxyuridine A solution of E 5 2 bromovinyl 3 ,5 di O tert butoxycarbonylphenylalanyl 2 deoxyuridine 100 mg, 0.12 mmol in dry ether 10 mL was treated with 98 sulphuric acid 14 pL, 0.26 mmol and stirred at 250 for 1 hour. The solvent was removed in vacuo and the residue stirred vigorously with ether 20 mL . The white solid was quickly filtered and dried.1Hnmr CD3 2O 2.32 2H, m, 2 CH2 , 3.1 4H, m, 2 xPhCH2 , 3.87 lH, m, 4 CH , 4.25 4H, m, 5 CH2 2 xPhCH2CH , 5.0 1H, m, 3 CH , 6.03 1H, t J 7.5Hz, 1 CH , 6.9 1H, d, J 14Hz, CH CHBr , 7.26 llH, m, aromatic CH CHBr , 7.8 1H, s, 6 CH , 8.47 6H, br.s, Q4D2O exchangeable, 2 x NH3 , 11.7 lH, br.s, D2O exchangeable, NH .AnalysisFound C, 41.91 H, 4.61 N, 6.29 S, 7.69.C29H35N4BrO15S2 requires C, 42.29 H, 4.28 N, 6.80 S, 7.79. Examples 11 and 12General Method for the Preparation of 3 ,5 di t butoxycarbonylaminoacyl esters of E 5 2 bromovinyl 2 deoxyuridine E 5 2 Bromovinyl 2 deoxyuridine 2 g, 6 mmol , N t butoxycarbonylamino acid N hydroxysuccinimide ester 5 g, 15 mmol and 4 dimethylaminopyridine 0.4 g, 3.3 mmol were stirred in dry tetrahydrofuran 150 mL at 800 for 24 hours. The solvent was removed under reduced pressure and the residue dissolved in chloroform 100 mL . The organic layer was washed with iRM hydrochloric acid 2 x 100 mL , cold saturaed sodium bicarbonate solution 2 x 100 mL and water 100 mL before drying Na2SO4 . The 3 ,5 di O t butoxy carbonylaminoacyl esters were normally isolated by column chromatography on silica gel. Example 11E 5 2 Bromovinyl 3 ,5 di t butoxycarbonyl p fluoroDL phenylalanyl 2 deoxyuridine Isolated as a white foam in 89 yield by column chromatography on silica gel eluting with chloroform methanol 50 1 . Tlc Rf 0.55 in chloroform methanol 30 1 max nujol 3350 NH , 1740, 1710 C O cm l 1H nmr CD3 2SO 1.35 18H, s, CH3 6 , 2.33 2H, m, 2 CH2 , 2.95 4H, m, 2xPhCH2 , 3.9 4.45 5H, m, 4 CH 5 CH2 2xCHNH , 5.16 1H, m, 3 CH , 6.15 1H, t,J 6Hz , 6.93 1H, d, J 14Hz, CH CHBr , 7.0 7.6 llH, m, aromatic 2xNHCH CH CHBr , 7.83 1H, s, 6 CH , 11.74 lH, s, D2O exchangeable, 3 NH .AnalysisFound C, 54.36 H, 5.23 N, 6.52 C39H45BrF2N4O11 requires C, 54.23 H, 5.25 N, 6.49 . Example 12E 5 2 Bromovinyl 3 ,5 di t butoxycarbonyl L leucyl 2 deoxyuridine Isolated as a white foam in 41 yield by column chromatography on silica gel eluting wtih chloroform methanol 50 1 and then a second column eluting with chloroform. Rf 0.42 in chloroform methanol 40 1 max nujol 3350 NH , 1745, 1700 C O cm l 1H nmr CD3 2SO 0.9 12H, m, 2x CH3 2CH , 1.4 18H, s, 2x CH3 3CO , 1.5 6H, m, 2xCH2CH CH3 2 , 2.42 2H, m, 2 CH2 , 3.98 2H, m, 2xCHNH , 4.2 3H, m, 5 CH2 4 CH , 5.21 1H, m, 3 CH , 6.18 1H, t, J 6Hz, 1 CH , 6.91 1H, d, J 14Hz, CH CHBr , 7.35 1H, d,J 14Hz, CH CHBr , 7.4 2H, br.m, 2xNHCH , 7.82 1H, s, 6 CH , 11.7 1H, s, D2O exchangeable, 3 NH .AnalysisFound C, 52.26 H, 6.69 N, 7.41 C33H51BrN4O11 requires C, 52.17 H, 6.77 N, 7.38 . Examples 13 to 16The general deprotection reaction method of Examples 7 to 9 was used to prepared these Examples, with the following characterising data.Example 13E 5 2 Bromovinyl 5 glycyl 2 deoxyuridine trifluoroacetate Isolated in 88 yield. max nujol 1760, 1720, 1680 cm l 1H nmr CD3 2SO s 2.27 2H, m, 2 CH2 , 3.85 2H, m,CH2NH3 , 4.1 4.8 4H, m, 5 CH2 3 CH 4 CH , 5.95 1H, br.s, D2O exchangeable, OH , 6.2 1H, t, J 6Hz, 1 CH , 6.94 1H, d, J 14Hz, CH CHBr , 7.4 1H, d,J 14Hz, CH CHBr , 7.8 1H, s, 6 CH , 8.3 3H, br.s, D2O exchangeable, NH3 , 11.6 1H, s, D2O exchangeable, 3 NH .AnalysisFound C, 36.65 H, 3.48 N, 7.94 C15H17BrF3N3O8 requires C, 35.73 H, 3.40 N, 8.33 . Example 14E 5 2 Bromovinyl 3 ,5 di glycyl 2 deoxyuridine bis trifluoroacetate Isolated in 96 yield. max nujol 1760, 1720, 1680 cm 1, 1H nmr CD3 2SO S 2.51 2H, m, 2 CH2 , 3.9 4H, s, 2xCH2 , 4.2 4.7 3H, m, 5 CH2 4 CH , 5.4 1H, m, 3 CH , 6.24 1H, t, J 6Hz, 1 CH , 6.93 1H, d,J 14Hz, CH CHBr , 7.4 1H, d, J 14Hz, CH CHBr , 8.52 7H, br.s, D2O exchangeable, 2 x NH3 NH .AnalysisFound C, 34.21 H, 2.91 N, 8.08 C19H21BrF6N4O11 requires C, 33.79 H, 3.13 N. 8.30 . Example 15 E 5 2 Bromovinyl 3 ,5 t di p fluoro DL phenylalanyl 2 deoxyuridine bis trifluoroacetate Isolated in 94 yield. iimax nujol 1755, 1710, 1680 cm 1 1H nmr CD3 2SO3 2.3 2H, m, 2 CH2 , 3.1 4H, m, 2xPhCH2 , 3.7 4.6 5H, m, 4 CH 5 CH2 2xCHCH2 , 5.23 1H, m, 3 CH , 6.13 1H, t, J 6Hz, 1 CH , 6.8 7.5 10H, m, aromatic CH CHBr , 7.9 1H, s, 6 CH , 8.7 7H, br.s, D2O exchangeable, 2xNH3 NH .AnalysisFound C, 44.94 H, 3.56 N. 6.42 C33H31BrF8N4O11 requires C, 44.46 Hr 3.51 N, 6.28 . Example 16E 5 2 Bromovinyl 3 ,5 di L leucyl 2 deoxyuridine trifluoroacetate Isolated in 87 yield. max nujol 1760, 1730, 1680 cm 1, 1H nmr CD3 2SO 0.9 12H, m, 4xCH3 , 1.64 6H, m, 2xCH2CH CH3 2 , 2.45 2H, m, 2 CH2 , 4.0 2H, m, 2xCHNH , 4.38 3H, m, 5 CH2 4 CH , 5.35 1H, m, 3 CH , 6.24 lH, t, J 14Hz, CH CHBr , 6.88 1H, d,J 14Hz, CH CHBr , 7.34 1H, d, J 14Hz, CH CHBr , 7.9 lH, s, 6 CH , 8.65 7H, br.s, D2O exchangeable, 2xNH3 NH .AnalysisFound C, 40.63 H, 4.95 N. 7.00 C27H37BrF6N4O11 requires C, 41.18 H, 4.74 N, 7.11 . Example 17E 5 2 Bromovinyl 3 ,5 di glycyl 2 deoxyuridine bis bisulphate A solution of E 5 2 bromovinyl 3 ,5 di t butoxycarbonylglycyl 2 deoxyuridine Example 4 323 mg, 0.5 mmol in dry ether 5 mL was treated with 98 sulphuric acid 57 pL, 1.07 mmol and stirred at 0 for 15 minutes. The deposited solid was filtered of f, washed well with ether and dried to give E 5 2 bromovinyl 3 ,5 di glycyl 2 deoxyuridine bis bisulphate in 31 yield. max nujol 1760, 1720, 1680 cm l ÚH nmr CD3 2SO 2.5 2H, m, 2 CH2 , 3.89 4H, m, 2xCH2 , 4.4 3H, m, 5 CH2 4 CH , 5.39 lH, m, 3 CH , 6.21 1H, t, J 6Hz , 1 CH , 6.89 1H, d,J 14Hz, CH CHBr , 7.38 1H, d, J 14Hz, CH CHBr , 7.9 1H, s, 6 CH , 8.3 8.68 9H, m, D2O exchangeable, 2 xNH3 2HSO4 NH .AnalysisFound C, 28.19 H, 3.76 N, 7.99 C15H23BrN4O15S2 requires C, 28.00 H, 3.60 H, 8.71 . Bromovinyl 3 ,5 di L leucyl 2 deoxyuridine bis A solution of E 5 2 bromovinyl 3 ,5 di t butoxycarbonyl L leucyl 2 deoxyuridine Example 12 250mg, 0.3mmol in dry ether 10 mL was treated with 98 sulphuric acid 36 L, 0.66 mmol and stirred at 0 for 15 minutes.The solvents were removed under reduced pressure and the residual foam triturated well with ether to give E 5 2Bromovinyl 3 ,5 di L leucyl 2 cecxyuridine bis bisulphate salt as a white solid in 99 yield. max nujol 1760, 1670 1730, 1600 cm 1H nmr CD3 2SO 6 0.9 12H, m, 4 x CH3 , 1.67 6H, m, 2 x CH2CH , 2.5 2H, m, 2 CH , 4.0 2H, m, 2 x CHNH3 , 4.28 4.65 3H, m, 5 CH2 4 CH , 5.39 iH, m, 3 CH , 6.28 1H, t, J 6Hz, 1 CH , 6.95 1H, d,J 14Hz, CH CHBr , 7.49 1H, d, J 14Hz, CH CHBr , 7.65 2H, br.s, D2O exchangeable, 2HSO4 , 7.91 1H, s, 6 CH , 8.39 6H, br.s, D2O exchangeable, 2 x NH3 , 11.78 1H, s, D2 0 exchangeable, 3 NH .AnalysisFound C, 36.87 H, 5.40 N, 6.92 4. C23H39BrN4O15S2 requires C, 36.56 H, 5.20 N, 7.42 . General Method for the Preparation of 3 ,5 Di t butoxy carbonylaminoacyl esters of E 5 2 Bromovinyl 2 deoxy uridine Examples 19 23 . E 5 2 Bromovinyl 2 deoxyuridine 2g, 6mmol , N tbutoxycarbonylamino acid N hydroxysuccinimide ester 5g, 15 mmol and 4 dimethylaminopyridine 1.83g, 15mmol were stirred in dry tetrahydrofuran 200mL at 800 for 24 hours. The solvent was removed under reduced pressure and the residue dissolved in chloroform 200mL . The organic layer was asTh ed with 1M hydrochloric acid 2 x 150mL cold saturated sodium bicarbonate solution 2 x 150mL and water 150mL before drying Na2SO4 . The solvent was removed under reduced pressure affording a foam. The 3 ,5 di t butoxycarbonylaminoacyl esters were isolated by column chromatography on silica gel. The following compounds were isolated by this method Example No. Yield g Example 19E 5 2 Bromovinyl 3 ,5 di t butoxy 78 carbonyl D leucyl 2 deoxyuridineExample 20E 5 2 Bromovinyl 3 ,5 di t butoxy 50 carbonyl D phenylalanyl 2 deoxyuridine Example 21E 5 2 Bromovinyl 3 ,5 di t butoxy 59 carbonyl l methionyl 2 deoxyuridine Example 22E 5 2 Bromovinyl 3 ,5 di t butoxy 51 carbonyl L valyl 2 deoxyuridine Example 23E 5 2 Bromovinyl 3 ,5 di t butoxy 36 carbonyl L isoleucyl 2 deoxyuridine Example 19 E 5 2 Bromovinyl 3 ,5 di t butoxycarbonyl D leucyl 2 deoxyuridine T1c Rf 0.58 in ethyl acetate hexane 2 1 max nujol 3350, 1700 1750 broad cm 1 ÚH nmr CD3 2SO 0.85 12H, m, 4 x CH3 , 1.37 24H, m, 2 x C CH3 3 2 x CH2CH , 2.37 2H, m, 2 CH2 , 3.93 2H, m, 2 x CHNH , 4.14 1H, m, 4 CH , 4.27 2H, m, 5 CH2 , 5.19 1H, m, 3 CH , 6.14 1H, t, J 6Hz, 1 CH , 6.88 1H, d, J 14 Hz, CH CHBr , 7.29 1H, d, J 14Hz, CH CHBr , 7.3 2H, br.m, 2 xEMI31.1 7.8 1H, s, 6 CH , 11.66 1H, s, D2O exchangeable, 3 NH Analysis Found C, 52.39 H, 6.81 N, 7.37 . C33H51BrN4O11 requires C, 52.17 H, 6,77 N, 7.38 .Example 20E 5 2 Bromovinyl 3 ,5 di t butoxycarbonyl D phenylalanyl 2 deoxyuridine Tlc Rf 0.26 in ethyl acetate hexane 2 3 vmax nujol 3340, 1700 1750 broad cm 1 1H nmr CD3 2SO 6 1.27 18H, s, 6 x CH3 , 2.2 2H, m, 2 CH2 , 2.9 4H, m, 2 x PhCH2 , 3.9 4.3 5H, m, 5 CH2 4 CH 2 x CHCH2 , 5.1 1H, m, 3 CH , 6.02 1H, t, J 6Hz, 1 CH , 6.88 1H, d,J 14Hz, CH CHBr , 7.26 13H, m, aromatic CH CHBr 2 xEMI31.2 7.78 1H, s, 6 CH , 11.68 1H, br.s, D20 exchangeable, 3 NH . Analysis Found C, 56.51 H, 5.65 N, 6.49 . C39H37BrN4O11 requires C, 56.59 H, 5.72 N, 6.76 . Example 21E 5 2 Bromovinyl 3 ,5 di t butoxycarbonyl L methionyl 2 deoxyuridine T1c Rf 0.31 in chloroform methanol 50 1 max nujol 3340, 1680 1750 broad , 1600 cm 1 ÚH nmr CD3 2SO 1.38 18H, s, 2 x C CH3 3 , 1.9 4H, m, 2 x CH2CH , 2.02 3H, s, SCH3 , 2.05 3H, s, SCH3 , 3.95 4.4 5H, m, 5 CHs 4 CH 2 x CHNH , 5.26 1H, m, 3 CH , 6.19 1H, t, J 6Hz, 1 CH , 6.9 1H, d, J 14Hz, CH CHBrEMI32.1 d,J 14Hz, CH CHBr , 7.4 2H, m, 2 x 7.82 1H, s, 6 CH , 11.7 1H, s, D2O exchangeable, 3 NH .AnalysisFound C, 47.40 H, 5.61 N, 6.83 . C31H47BrN4O11S2 requires C, 46.79 H, 5.95 N, 7.04 .Example 22E 5 2 Bromovinyl 3 ,5 di t butoxycarbonyl L valyl 2 deoxyuridine Tic Rf 0.31 in ethyl acetate hexane 1 2 max nujol 3350, 1700 1750 broad , 1600 cm 1 ÚH nmr CD3 2SO 6 0.87 12H, m, 4 x CH3 , 1.35 18H, s, 2 xC CH3 3 , 1.96 2H, m, 2 x CH CH3 2 , 2.39 2H, m, 2 CH2 , 3.78 2H, m, 2 x CHNH , 4.18 1H, m, 4 CH , 4.27 2H, m, 5 CH2 , 5.22 1H, m, 3 CH , 6.19 1H, t, J 6Hz, 6.89 1H, d, J 14Hz, CH CHBr , 7.2 2H, m, 2EMI32.2 7.3 1H, d, J 14Hz, CH CHBr , 7.8 1H, s, 6 CH , 11.7 1H, s, D2O exchangeable, 3 NH .AnalysisFound C, 51.08 H, 6.17 N, 7.57 . C31H47BrN4O11 requires C, 50.89 H, 6.48 N, 7.66 . Example 23E 5 Bromovinyl 3 ,5 di t butoxycarbonyl L isoleucyl deoxyuridine T1c Rf 0.26 in chloroform methanol 50 1 max nujol 3350, 1700 1750 broad , 1600 cm 1 1H nmr CD3 2SO 6 0.8 12H, m, 4 x CH3 , 1.2 2.0 24H, m, 2 X C CH393 2 x CH2 2 x CHCH3 , 2.31 2H, m, 2 CH , 3.8 2H, m, 2 x CHNH , 4.1 4.4 3H, m, 5 CH3 4 CH , 6.1 1H, t, J EMI33.1 6.8 1H, d, J 14Hz, C CHBr , 7.2 2H, m, 2 xCH3 3 , 7.24 1H, d, J 14Hz, CH CHBr 7.73 1H, s, 6 CH , 11.66 1H, s, 3 NH .AnalysisFound C, 51.93 H, 6.64 N, 7.32 . C33H51BrN4O11 requires C, 52.17 H, 6.77 N, 7.33 . Method for the Preparation of 3 ,5 bi t Butoxy carboxylaminosoyl esters of E 5 2 Bromovinyl 2 deoxy uridine Examples 24 26 E 5 2 Bromovinyl 2 deoxyuridine 2g, 6mmol , N tbutoxycarbonylamino acid p nitrophenyl ester 5g 15 mmol and 4 dinethylaminopyridine 1.83g, 15mmol were stirred together in dry tetrahydrofuran 200mL at 800 for 24 hours.The solvent was removed under reduced pressure and the residue dissolved in chloroform 200mL . The organic layer was washed with 1M hydrochloric acid 2 x 150mL , cold saturated sodium bicarbonate solution 2 x 150mL and water 150mL before drying Na2SO4 . The solvent was removed under reduced pressure affording a foam. The 3 ,5 di t butoxycarbonylaminoacyl esters were isolated by column chromatography on silica gel. The following compounds were isolated by this method.Example No. Yield Example 24E 5 2 Bromovinyl 3 ,5 di t butoxy 56 carbonyl L alanyl 2 deoxyuridine Example 25E 5 2 Bromovinyl 3 ,5 di t butoxy 14 carbonyl L glutaminyl 2 deoxyuridineExample 26 E 5 2 Bromovinyl 3 ,5 bis Nss,N di t 51 butoxycarbonyl L lysyl 2 deoxyuridine Example 24 2 Bromovinyl 3 ,5 di 5 butoxycarbonyl L alanyl Tic Rf 0.47 in chloroform methanol 10 1 max nujol 3330 NH , 1750, 1700 C 0 cm 1 ÚH nmr CD3 2SO 1.2 1.4 24H, m, 2 x C CH3 3 2 x CH3 , 2.40 2H, m, 2 CH2 , 3.84 4.37 5H, m, 5 CH2 4 CH 2 x CHNH , 5.22 1H, m, 3 CH , 6.15 1H, t, J 6Hz,EMI35.1 6.86 1H, d, J 14Hz, CH CHBr , 7.3 2H, m, 2 x 7.3 1H, d,J 14Hz, CH CHBr , 7.76 1H, s, 6 CH , 11.66 1H, br.s,D2O exchangeable, 3 NH .AnalysisFound C, 48.59 H, 5.78 N, 8.15 . C27H39N4O11Br requires C, 48.01 H, 5.82 N, 8.29 .Example 25E 5 2 Bromovinyl 3 ,5 di t butoxycarbonyl L glutaminyl 2 deoxyuridine Tlc Rf 0.15 in chloroform methanol 10 1 max nujol 3380, 3350, 3250, 3200 NH , 1730, 1720, 1690, 1675, 1660 C 0 cm 1 ÚH nmr CD3 2SO 1.4 18H, m,EMI35.2 3 3 , 1.87 4H, m, 2 x CH2CH , 2.12 4H, m, 2 x 2.42 2H, m, 2 CH2 , 3.95 2H, m, 2 x CHNH , 4.24 3H, m, 5 CH2 4 CH , 5.25 1H,EMI35.3 1H, t, J 6Hz, 1 CH , 6.73 2H, br.s, 2 x 6.9 1H, d, J 14Hz, CH CHBr , 7.27 4H, 7. 34 1H, d, J 14Hz, CH CHBr , 7.8 1H, s, 6 CH , 11.74 1H, s, D20 exchangeable, 3 NH . AnalysisFound C, 47.25 H, 5.42 N, 10.56 . C31H45BrN6O13 requires C, 47.15 H, 5.74 N, 10.64 . Example 35 E 5 2 Bromovinyl 3 ,5 bis Nss,N di t butoxycarbonyl L lysyl 2 deoxyuridine T1c Rf 0.31 in chloroform methanol 20 1 max nujol 3350 NH , 1730, 1700 C cm 1 ÚH nmr CD3 2SO 1.3 1.75 48H, m, 4 x C CH3 3 6 x CH2 , 2.33 2K, m, 3.86 2H, m, 2 x CHNH , 4.18 3H, m, 5 CH2 4 CH ,EMI36.1 3 CH , 6.15 1H, t, J 6Hz, 1 CH , 6.65 2H, 6.87 1H, d, J 14Hz, CH CHBr , 7.2 2H, m, 3 1H, d, J 14Hz, CH CHBr , 7.76 1H, s, 6 CH , 11.65 1H, br.s, D2O exchangeable, 3 NH .AnalysisFound C, 51.88 H, 7.01 N, 8.22 . C43H69N6O15Br requires C, 52.17 H, 7.03 N, 8.49 . 28 and 29 Reaction of E 5 2 bromovinyl 2 deoxyuridine withN t butoxycarbonyl L proline N hydroxysuccinimide ester was carried out under conditions identical to those described for the preparation of Examples 19 23. The following three products were isolated by column chromatography on silica gel, eluting with chloroform methanol 50 1 .Example 27E 5 2 Bromovinyl 3 ,5 di t butoxycarbonyl L prolyl 2 deoxyuridine Isolated in 43 yield. Tic Rf 0.49 in chloroform methanol 20 1 max nujol 1690 1740 broad , 1755, 1600 cm 1 ÚH nmr CD3 2SO 1.38 18H, m, 2 x C CH3 3 1.85 8H, m, 4 x CH2 , 2.33 2H, m, 2 CH2 , 3.3 4H, m, 2 x CH2 N , 4.0 4.4 5H, m, 4 CH 5 CH2 2 x CHNH , 5.3 1H, m, 3 CH , 6.2 1H, t, J 6Hz, 1 CH , 6.94 1H, d,J 14Hz, CH CHBr , 7.4 1H, d, J 14Hz, CH CHBr , 7.87 1h, s, 6 CH , 11.73 1H, s, D20 exchangeable, 3 NH .AnalysisFound C, 51.25 H, 5.14 N, 7.48 . C31H43BrN4O11 requires C, 51.17 H, 5.96 N, 7.70 .Example 28E 5 2 Bromovinyl 5 5 butoxycarbonyl L prolyl 2 deoxyuridine Isolated in 8 yield. Tic Rf 0.17 in chloroform methanol 20 1 max nujol 3400, 1680 1750 broad , 1600 cm 1 ÚH nmr CD3 2SO 1.35 9H, m, C CH3 3 , 1.72 4H, m, 2 x CH2 , 2.13 2H, m, 2 CH2 , 3.24 2H, t, J 6Hz,CH2 N , 3.9 4.3 5H, m, 5 CH2 4 CH 3 CH CHN , 6.13 1H, t,J 6Hz, 1 CH , 6.9 1H, d, J 14Hz, CH CHBr , 7.3 1H, d, J 14Hz, CH CHBr , 7.75 1H, s, 6 CH , 11.64 1H, s, D2O exchangeable, 3 NH . analysisFound C, 47.58 H, 4.87 K, 7.61 . C21H26SrK3O8 requires C, 47.56 H, 5.32 N, 7.92 .Example 29E 5 2 Bromovinyl 3 t butoxycarbonyl L prolyl 2 deoxyuridine Isolated in 9 yield. Tic Rf 0.33 in chloroform methanol 20 1 max nujol 3400, 1680 1750 broad , 1600 cm 1 ÚH nmr CD3 2SO 0.4 9H, m, C CH3 3 , 1.85 4H, m, 2 x CH2 , 2.36 2H, m, 2 CH2 , 3.34 2H, m,CH2 N , 3.64 2H, m, 5 CH2 , 3.9 4.3 2H, m, 4 CH 2 x CHN , 5.28 lH, m, 3 CH , 6.18 1H, t, J 6Hz, 1 CH , 6.86 1H,J J 14Hz, CH CHBr , 7.3 1H, d, J 14Hz, CH CHBr , 8.1 1H, s, 6 CH , 11.63 1H, s, D2O exchangeable, 3 NH AnalysisFound C, 47.16 H, 5.36 N, 7.52 . C21H28BrN3O8 requires C, 47.56 H, 5.32 N, 7.92 . 1H, s, 3 CH , 6.26 1H, t, J 6Hz, 1 OH , 6.9 1H, d,J 14Hz, CH CHBr , 7.4 1H, d, J 14Hz, CH CHBr , 7.93 OH, s, 6 CH , 8.65 6H, br.s, L2O exchangeable, 2 x NH3 , 11.6 1H, s, D2O exchangeable, 3 NH .AnalysisFound C, 36.39 H, 3.96 N, 6.32 . C25H33BrF6N4O11S2 requires C, 36.46 H, 4.04 N, 6.80 .Example 33E 5 2 Bromovinyl 3 ,5 di L valyl 2 deoxyuridine bis trifluoroacetate max nujol 1750, 1670 1740, 1620, 1600 cm 1 ÚH nm CD3 2SO 0.95 12H, m, 4 x CH3 , 2.0 2.5 4H, m, 2 CH2 2 x CH CH3 2 , 3.9 2H, t, J 6Hz, 2 x CHNH3 , 4.27 1H, m, 4 CH , 4.4 2H, m, 5 CH2 , 5.4 1H, m, 3 CH , 6.27 1H, t, J 6Hz, 1 CH , 6.9 1H, d, J 14Hz, CH CHBr , 7.35 1H, d, J 14Hz, CH CHBr , 7.94 1H, s, 6 CH , 8.91 7H, br.s,D2O exchangeable, 2 x NH 3 NH .AnalysisFound C, 39.78 H, 4.16 N, 7.41 . C25H33BrF6N4O11 requires C, 39.54 H, 4.38 N, 7.38 .Example 34 E 5 2 Bromovinyl 3 ,5 di L isoleucyl 2 deoxyuridine his trifluoroacetate max nujol 1760, 168ss 1740, 1600 cm 1 ÚH nmr CD3 2SO 6 0.9 12H, m, 4 x CH3 , 1.35 4H, m, 2 xCH2CH3 , 1.86 2H, m, 2 x CHCH3 2.4 2H, m, 2 CH2 , 4.0 2H, t, J 6Hz , 2 x CHNH3 , 4.3 1H, m, 4 CH , 4.45 2H, m, 5 CH2 , 5.39 1H, m, 3 CH , 6.26 1H, t, J 6Hz, 1 CH 6.88 1H, d, J 14Hz, CH CHBr , 7.36 1H, d, J 14Hz,CH CHBr , 7.91 1H, s, 6 CH , 8.6 6H, br.s, D2O exchangeable, 2 x NH3 , 11.7 1H, s, D2O exchangeable, 3 NH .AnalysisFound C, 40.89 H, 4.74 N, 7.06 . C27H37BrF6N4O11 requires C, 41.18 H, 4.74 N, 7.11 . Example 35E 5 2 Bromovinyl 3 ,5 di L prolyl 2 deoxyuridine bis trifluoroacetate max nujol 1760, 1680 1740, 1600 cm 1 ÚH nmr CD3 2SO 1.8 2.5 10H, m, 4 x CH2 2 CH2 , 3.26 4H, t, J 6Hz, 2 x CHNH2 , 5.35 1H, m, 3 CH , 6.2 1H, t,J 6Hz, 1 CH , 6.9 1H, d, J 14Hz, CH CHBr , 7.34 1H, d, J 14Hz, CH CHBr , 7.9 1H, s, 6 CH , 9.62 4H, br.s,D2O exchangeable, 2 x NH2 .AnalysisFound C. 39.47 H, 3.81 N, 7.33 . C25H29BrF6N4O11Requires C, 39.75 H, 3.87 N, 7.42 .Example 36E 5 2 Bromovinyl 5 L prolyl 2 deoxyuridine trifluoroacetate max nujol 1760, 1670 1740, 1600 cm 1, ÚH nmr CD3 2SO 6 1.91 4H, m, 2 x CH2 , 2.24 2H, m, 2 CH2 , 3.21 2H, m, CH2 NH2 , 3.93 1H, m, 4 CH , 4.37 3H, m, 5 CH2 3 CH , 5.65 1H, br.s, D2O exchangeable, OH , 6.17 1H, t, J 6Hz, 1 CH , 6.9 1H, d, J 14Hz, CH CHBr , 4.32 1H, d, J 14Hz, CH CHBr , 9.4 5H, br.s, D2O exchangeable, 2 x NH2 3 NH .AnalysisFound C, 39.77 H, 3.69 N, 7.63 . C18H21BrF3N3O8 requires C, 39.73 H, 3.89 N, 7.72 .Example 37E 5 2 Bromovinyl 3 L prolyl 2 deoxyuridine trifluoroacetate max nujol 1750, 1670 1740, 1600 cm 1 ÚH nmr CD3 2SO 1.95 4H, m, 2 x CH2 , 2.3 2H, m, 2 CH2 , 3.22 2H, m, CH2NH2 , 3.65 2H, m, 5 CH2 , 4.1 1H, m, 4 CH , 4.15 4.8 2H, m, CHNH2 OH , 5.34 1H, m, 3 CH , for the trifluoroacetic acid deprotection of E 5 2 Bromovinyl 2 deoxyuridine 5 3 and 3 ,5 di N butoxycarbonylaminoacyl esters Examples 30 39 A solution of E 5 2 bromovinyl 2 deoxyuridine 5 3 cr 3 ,5 di t butoxycarbonylaminoacyl ester 0.5mmol in trifluoroacetic acid 2mL was stirred at 0 for 15 minutes. Te solvent as removed under reduced pressure and the foamy residue triturated twice with dry ether to give the salts as white solids. The following compounds were prepared by this method. Example No. Yield Example 30E 5 2 Bromovinyl 3 ,5 di D leucyl 92 2 deoxyuridine bis trifluoroacetate xar . rle 31E 5 2 Bromovinyl 3 ,5 di D phenylalanyl 87 2 deoxyuridine bis trifluoroacetateExample 32E 5 2 Bromovinyl 3 ,5 di L methionyl 94 2 deoxyuridine bis trifluoroacetateExample 33E 5 2 Bromovinyl 3 ,5 di L valyl 91 2 deoxyuridine bis trifluoroacetateExample 34E 5 2 Bromovinyl 3 ,5 di L isoleucyl 82 2 deoxyuridine bis trifluooracetateExample 35E 5 2 Bromovinyl 3 ,5 di L prolyl 96 2 deoxyuridine bis trifluoroacetateExample 36 E 5 2 Bromovinyl 5 L prolyl 2 98 decxyuridine trifluoroacetateExample 37 2 Bromovinyl 3 L prolyl 2 97 deoxyuridine trifluoroacetate Ex Tiple 38E 5 2 Bromovinyl 3 ,5 di L alanyl RTI ID 41.9 2 deoxyuridine bis trifluoroacetateExample 39 E 5 2 Bromovinyl 3 ,5 di L glutamyl 93 Example 30 E 5 2 Bromovinyl 3 ,5 di D leucyl 2 deoxyuridine bis trifluoroacetate max nujol 1755, 1670 1740 broad , 1600 cm 1 ÚH nmr CD3 2SO 0.9 12H, m, 4 x CH3 , 1.65 6H, m, 2 x CH2CH , 2.45 2H, m, 2 CH2 , 4.03 1H, m, 2 x CHNH3 , 4.2 4.5 3H, m, 5 CH2 4 CH , 5.36 1H, m, 3 CH , 6.24 1H, t, J 6Hz, 1 CH , 6.9 1H, d, J 14Hz, CH CHBr , 7.36 1H, d, J 14Hz, CH CHBr , 7.93 1H, s, 6 CH , 8.6 7H, br.s, D2O exchangeable, 2 x NH3 3 NH .AnalysisFound C, 41.43 H, 4.57 N, 7..18 B. C27H37BrF6N4O11 requires C, 41.18 H, 4.74 N, 7.11 .Example 31E 5 2 Bromovinyl 3 ,5 di D phenylalanyl 2 deoxyuridine bis trifluoroacetate nujol 1760, 1680 1740 broad cm 1 ÚH CD3 2SO 6 2.15 2H, m, 2 CH2 , 3.2 4H, m, 2 x PhCH2 , 4.1 4.6 5H, m, 4 CH 5 CH2 2 x CHCH2 , 5.25 1H, m, 3 CH , 6.14 1H, t, J 6Hz, 1 CH , 6.94 1H, d, J 14Hz,CH CHBr , 7.35 11H, m, aromatic CH CHBr , 7.94 1H, s, 6 CH , 8.7 7H, br.s, D20 exchangeable, 2 x NH3 3 NH .AnalysisFound C, 46,11 H, 3.90 N, 6.48 . C33H33BrF6N4O11 requires C, 46.33 Hm 3.89 N, 6.55 .xample 32 E 5 2 Bromovinyl 3 ,5 di L methionyl 2 eoxyuridine bis trifluoroacetate max nujol 1760, 1650 1740, 1600 cm 1 ÚH nmr CD3 2SO 2.0 3H, s, CH3S , 2.07 3H, s, CH3S , 2.1 4H, m, 2 x CH2CH , 2.55 4H, m, 2 CH2 2 x CH2S , 4.17 2H, m, 2 x CHNH3 , 4.3 4.6 3H, m, 5 CH2 4 CH , 5.37 7.2 1H, t, J 7Hz, 1 CH , 6.05 1H, d, J 14Hz, CH CHBr , 7.27 1H, d, J 14Hz, CH CHBr , 8.1 1H, s, 6 CH , 9.5 5H, br.s, D2O exchangeable, 2 x NH2 3 NH .Analysis Found C, 40.06 H, 3.44 N, 7.35 . C18H21BrF3N3O8 requires C, 39.72 H, 3.89 N, 7.72 .Example 38 E 5 2 Bromovinyl 3 ,5 di L alanyl 2 deoxyuridine bis trifluoroacetate Lmax nujol 1760, 1670 1730, 1600 cm 1H nmr CD3 2SO Ï 1.46 6H, d, J 7.5Hz, 2 x CH3 , 2.48 2H, m, 2 CH2 , 4.13 2H, m, 2 x CHH3 , 4.27 1H, m, 4 CH , 4.4 2H, in, 5 CH2 , 5.37 1H, m, 3 CH , 6.2 1H, t, J 6Hz, 1 CH , 6.89 1H, d, J 14Hz, CH CHBr , 7.33 TH, d,J 14Hz, CH CHBr , 7.9 1H, s, 6 CH , 8.57 6H, br.s, D2O exchangeable, 2 x NH3 , 11.68 H, Br.s, D2O exchangeable, 3 NH .AnalysisFound C, 34.89 H, 3.40 N, 7.46 . C21H35BrF6N4O11 requires C, 35.56 H, 3.55 N, 7.90 .Example 39E 5 2 Bromovinyl 3 ,5 di L glutamyl 2 deoxyuridine bis trifluoroacetate max nujol 1760, 1660 1630 cm 1 ÚH nmr CD3 2SO 6 2.05 4H, m, 2 x CH2CH , 2.28 4H, m, 2 x CH2CNH2 , 2.45 2H, m, 2 CH , 4.15 2H, m, 2 x CHNH3 , 4.35 1H, m, 4 CH 4.5 2H, m, 5 CH2 , 5.39 1H, m, 3 CH 6.24 1H, t,J 6Hz, 1 CH , 6.94EMI43.1 6.95 1H, br.s, D2O exchangeable 4Hz,CH CHBr , 7.39 1H, br , 7.87 1H, s, 6 CH , 8.54 6E, br.s, D20 exchangeable, 2 x NH3 , 11.76 1H, br.s, D2O exchangeable, 3 NH .AnalysisFound C, 37.19 H, 4.00 N, 8.90 . C25H31BrF6N6013 requires C, 36.73 H, 3.82 N, 10.27 . Example 4ss E 5 2 Bromovinyl 3 ,5 di L lysyl 2 deoxyuridine tetrakis trifluoroacetate A solution of E 5 2 bromovinyl 3 ,5 bis N alpha ,N t butoxycarbonyl L lysyl 2 deoxyuridine example 26 600mg, 0.61 mmol in trifluoroacetic acid 6mL was stirred at 0 for 30 minutes.The solvent was removed under reduced pressure and the foamy residue triturated with dry ether to give a white solid which was dissolved in water 10 mL and freeze dried to give E 5 2 bromovinyl 3 ,5 di L lysyl 2 deoxyuridine tetrakis trifluoroacetate dihydrate as a white foam in 60 yield 380mg . vmax nujol 1760, 16001730 cm 1 ÚH nmr CD3 2SO 1.45 8H, m, 2 x H3NCH2 CH2 2 , 1.74 4H, m, 2 x .CH2CH , 2.7 4H, m, 2 x CH2NH3 , 3.95 2H, m, 2 x CHNH3 , 4.28 1H, m, 4 CH , 4.4 2H, m, 5 CH2 , 5.33 1H, m, 3 CH , 6.19 1H, t, J 6Hz, 1 CH , 6.84 1H, d,J 14Hz, CH CHBr , 7.3 1H, a, J 14Hz, CH CHBr , 7.83 1H, s, 6 CH , 8.2 12H, br.s, D2O exchangeable, 4 x 11.65 1H, br.s, D2O exchangeable, 3 NH ,AnalysisFound C, 34.47 H, 4.18 N, 7.71 . C31H41BrF12N6O15 .2H2O requires C, 34.41 H, 4.16 N, 7.77 . Example 41 E 5 2 Bromovinyl 3 ,5 di L leucyl 2 deoxyuridine bis trihydrogenpyrophosphate A solution of E 5 2 bromovinyl 3 ,5 di t butoxycarbonyl L leucyl 2 deoxyuridine 150 mg, 0.2mmol in dry ether 25mL , was treated with a solution of pyrophosphoric acid 80mg, 0.45mmol in dry tetrahydrofuran 5mL and the solution stirred at room temperature for 1 hour. The solvent was removed under reduced pressure and the oily residue triturated twice with ether affording E 5 2 bromovinyl 3 ,5 di L leucyl 2 deoxyuridine bis trihydrogenphosphate 92mg, 51 as a white solid. vmax nujol 1760, 1700, 1680 cm 1 1H nmr CD3 2SO s0.94 12H, m, 4xCH3 , 1.64 2xCH2CH CH3 2 , 2.47 2H, m, 2 CH2 , 3.95 2H, m, 2xCHNH3 , 4.15 4.6 3H, m, 4 CH 5 CH2 , 5.38 1H, m, 3 CH , 6.21 1H, m, 1 CH , 6.88 1H, d, J 14Hz, CH CHBr , 7.35 1H, d, J 14Hz,CH CHBr , 7.85 1H, s, 6 CH , 7.95 13H, m, D2O exchangeable, 2xNH3.H3P2O7 3NH .Analysis Found C, 31.21 H, 4.79 N, 5.61 . C23H43BrN4021P4 requires C, 30.18 H, 4.73 N, 6.12 . Example 42 E 5 2 Bromovinyl 3 ,5 di L leucyl 2 deoxYuridine bis formate A solution of E 5 2 bromovinyl 3 ,5 di t butoxycarbonyl L leucyl 2 deoxyuridine 300 mg, 0.4mmol was dissolved in formic acid 8mL and the solution stirred at room temperature for 3 hours. The solvent was removed under high vacuum with a bath temperature less than 30 C. The oily residue was repeatedly triturated with dry ether until a white solid formed and E 5 2 bromovinyl 3 ,5 di L leucyl 2 deoxyuridine bis formate 210mg, 82 filtered off. i max nujol 1760, 1700, 1680 cm l 1H nmr CD3 2SO 0.89 12H, m, 4xCH3 , 1.40 4H, m, 2xCH9CH , 1.64 2H, m, 2xCH CH3 2 , 2.4 2H, m, 2 CH2 , 3.43 2H, t,J 6Hz, 2xCHNH3 , 4.27 3H, m, 5 CH2 4 CH , 5.26 1H, m, 3 CH , 5.85 9H, m, D2O exchangeable, 2xNH3 HCO2 3NH , 6.16 1H, t, J 7Hz, 1 CH 6.88 1H, d, J 14Hz,CH CHBr , 7.3 1H, d, J 14Hz, CH CHBr , 7.83 1H, s, 6 CH .Analysis Found C, 45.98 H, 5.78 N, 8.07 . C25H39BrN4O11 requires C, 46.09 H, 6.03 N, 8.59 . ANTIVIRAL ACTIVITYIn VitroMethod Vero African Green Monkey Kidney cells were grown to confluence in 6 well multidishes, each well being 3.5 cm in diameter. The cells were incubated with Herpes simplex type 1 virus HFEM strain and overlaid with 0.5 mL of 0.9 agarose w v in maintenance medium containing the test compound at a range of concentrations from 3 pg mL in half log dilution steps. The virus infected cultures were then incubated at 370C for 6 days before fixing in 48 formaldehyde solution and staining with carbolfuchsin.The dishes were then examined to find what concentration of test compound causing a 50 reduction in the number of virus plaques formed PDDso value and the minimum concentration of test compound which killed the cell monolayer, leaving a clear zone devoid of cells and virus plaques MTD . ResultsEMI48.1 tb SEP PDD50 tb Example SEP No SEP PD so SEP SEP MTD SEP g mL SEP tb SEP g mL SEP M tb SEP 1 SEP 1.10 SEP 1.33 SEP 100 tb SEP 2 SEP 0.16 SEP 0.28 SEP 100 SEP tb SEP 3 SEP 0.25 SEP 0.43 SEP 100 tb SEP 4 SEP 1.95 SEP 3.01 SEP 7100 tb SEP 5 SEP 0.48 SEP 0.98 SEP 100 tb SEP 6 SEP 0.54 SEP 1.10 SEP 100 tb SEP 7 SEP 0.14 SEP 0.16 SEP 100 tb SEP 8 SEP 0.45 SEP 0.76 SEP 100 tb SEP 9 SEP 0.19 SEP 0.32 SEP 100 tb SEP 10 SEP 0.19 SEP 0.24 SEP 100 tb SEP 12 SEP 0.86 SEP 1.13 SEP 100 tb SEP 13 SEP 0.94 SEP 1.87 SEP 100 SEP tb SEP 14 SEP 0.36 SEP 0.53 SEP 100 SEP tb SEP 15 SEP 0.80 SEP 0.90 SEP 100 tb SEP 16 SEP 0.02 SEP 0.025 SEP 7100 tb SEP 17 SEP 0.47 SEP 0.76 SEP 100 tb SEP 18 SEP 0.28 SEP 0.37 SEP 100 tb SEP 19 SEP 1 SEP 0 SEP 100 tb SEP 20 SEP 100 SEP 100 tb SEP 21 SEP 1.71 SEP 2.15 SEP 100 tb SEP 22 SEP 100 SEP 100 tb SEP 23 SEP 100 SEP 100 tb SEP 24 SEP 0.62 SEP 0.92 SEP 100 tb SEP 25 SEP 0.47 SEP 0.60 SEP 100 SEP tb SEP 26 SEP 90 SEP 91 SEP 100 SEP tb SEP 27 SEP 3.51 SEP 4.83 SEP 100 tb SEP 28 SEP 2.12 SEP 4.00 SEP 100 tb SEP 29 SEP 0.64 SEP 1.21 SEP 100 tb SEP 30 SEP 0.16 SEP 0.20 SEP 100 tb SEP 31 SEP 0.55 SEP 0.64 SEP 100 tb SEP 32 SEP 0.26 SEP 0.32 SEP 100 SEP tb SEP 33 SEP 0.24 SEP 0.32 SEP 100 tb SEP 34 SEP 0.40 SEP 0.51 SEP w100 SEP tb SEP 35 SEP 0.22 SEP 0.29 SEP 100 tb SEP 36 SEP 0 55 SEP 1.01 SEP 100 tb SEP 37 SEP 0.68 SEP SEP 1.25 SEP 100 tb SEP 38 SEP 0.26 SEP 0.37 SEP 7100 SEP tb SEP 39 SEP 0.42 SEP 0.51 SEP 100 SEP tb SEP 40 SEP 0.19 SEP 0.18 SEP 100 tb SEP 41 SEP 0.55 SEP 0.60 SEP 100 tb SEP 42 tb